Immuron Ltd
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on developing and commercializing a novel class of specifically targeted polyclonal antibodies. The company aims to address significant unmet medical needs, particularly in treating gastrointestinal disorders caused by pathogenic bacteria. Immuron has established partnerships with leading research institutions and companies to enhance its product development and manufacturing capabilities. The company is currently advancing its drug candidates through clinical development, targeting conditions such as Campylobacteriosis, recurrent Clostridiodes difficile infections, and travelers’ diarrhea. Immuron is also engaged in various scientific studies and collaborations to further its research and product efficacy. The company has a proprietary technology platform and is committed to transforming treatment paradigms for gastrointestinal health.
Immuron Ltd
Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
What We Do
An over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders. It is sold in pharmacies throughout Australia and is also marketed in Canada and the U.S. Travelan enhances gastrointestinal system health and promotes immune defense. Clinical studies have shown it confers protection of up to 90% against infection with Enterotoxigenic E. coli. The active ingredient is hyperimmune bovine colostrum powder, which binds to E. coli in the gastrointestinal tract, preventing attachment and neutralizing its ability to cause diarrhea.
An immune supplement designed to help maintain healthy digestive function and liver. It is sold in practitioners’ offices in Australia and can be purchased online. Protectyn is listed on the Australian Register of Therapeutic Goods (AUST L 231001). It targets harmful bacteria and LPS toxins in the gut, helping to restore gut balance and support liver health. Protectyn is formulated to actively bind and efficiently remove specific bacteria and their LPS toxins from the body, which cannot be achieved with probiotics.
Hyper Immune Bovine Colostrum Powder
Produced in partnership with Synlait, this product is derived from colostrum collected from dairy cattle immunized with Immuron's proprietary vaccines. It is used in various formulations and is subject to stringent quality testing.
Application Area
Biologics
Key People
Chief Executive Officer
Chief Operating Officer
Chief Commercial Officer
Manufacturing Quality Director
Company Secretary & Chief Financial Officer
Research & Development Manager
News & Updates
Immuron reports record half yearly sales for its product Travelan, indicating strong market performance and demand.
Immuron has filed a pre-investigational new drug application with the U.S. FDA for a new treatment targeting Clostridioides difficile infections.
Immuron's Partnership with Synlait
Immuron collaborates with Synlait for the production of hyper immune bovine colostrum powder, ensuring high quality control and safety standards.
Immuron's Longstanding Partnership with the University of Melbourne
Immuron has a long-standing partnership with the University of Melbourne for research that led to the commercialization of Travelan.
Immuron and Tréidlia Biovet Collaboration
Immuron has partnered with Tréidlia Biovet since 2003 for the manufacture of ETEC vaccines, enhancing its veterinary vaccine offerings.
IMM-124E is the active pharmaceutical ingredient used to manufacture both Travelan® & Protectyn®. Randomized control trials showed protection of up to 90% against infection with E.coli (ETEC) and the development of Travelers’ Diarrhea.